Location of Repository

The Role of Endocannabinoids in Early Pregnancy

By Mark Finney

Abstract

The endocannabinoid N-arachidonoylethanolamine (anandamide; AEA) adversely affects early pregnancy initiation and maintenance in both animals and humans. Anandamide acting through the cannabinoid receptors CB1 and CB2 affects many aspects of reproduction and is formed on demand by the hydrolysis of N-arachidonoyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D (PLD) NAPE-PLD. Furthermore, AEA is catabolised by Fatty Acid Amide Hydrolase (FAAH). The aim of this thesis was to investigate how variations in the various components of the endocannabinoid system might lead to different early pregnancy outcomes. Using a newly developed UPLC-MS/MS method, plasma AEA levels were measured in women throughout pregnancy, compared to previous data and shown to be comparable. Moreover, women presenting with a viable pregnancy (on USS) with a threatened miscarriage (bleeding), who went on to miscarry and women presenting with a confirmed miscarriage (on USS) when compared with women with a viable pregnancy at the time of USS in whom there were no symptoms of miscarriage or those that went to term, all had increased plasma AEA levels. Median plasma AEA levels in the miscarriage group were 3-fold (p<0.001) higher than the levels in the live birth group. Using an AEA level of 2.0nM as cut-off for predicting subsequent miscarriage gave a sensitivity of 100% and a specificity of 94%, (negative predictive value 100%; positive predictive value 82%). Although other markers of pregnancy success (progesterone, hCG and PAPP-A) all gave the expected concentrations in on-going, failed and failing pregnancies, there was no statistically significant correlation between these factors and plasma AEA levels. Immunohistochemical evaluation of CB1, CB2, FAAH and NAPE-PLD expression in first trimester pregnancy tissues (trophoblast and decidua) showed that FAAH staining in the miscarriage/non-viable group was significantly lower than that in the surgical termination of pregnancy group. In women undergoing medical termination of pregnancy, using an anti-progesterone (mifepristone), FAAH staining was actually increased compared with that from the surgical termination of pregnancy group; whilst CB2 had increased staining and CB1 had reduced staining in the miscarriage and the medical termination groups when compared with the surgical termination of pregnancy group. There was no significant difference in NAPE-PLD staining between all three groups. These data provide new evidence that the endocannabinoid system plays a significant role in early pregnancy failure/miscarriage and that plasma AEA may be used as a future predictive marker for miscarriage. The lack of correlation between AEA and progesterone and the finding of elevated FAAH in the medical miscarriage (anti-progesterone) group, but low FAAH in spontaneous miscarriage suggest that factors other than progesterone are responsible for increased AEA levels in cases of miscarriage

Publisher: University of Leicester
Year: 2009
OAI identifier: oai:lra.le.ac.uk:2381/8686

Suggested articles

Preview

Citations

  1. (2006). {Delta}9-Tetrahydrocannabinol inhibits cytotrophoblast cell proliferation and modulates gene transcription.
  2. (2006). A biosynthetic pathway for anandamide.
  3. (2004). A novel slice variant involving the 5' untranslated region of thyroid hormone receptor 1 (TR1).
  4. (1996). A prospective study of early pregnancy loss.
  5. (1997). A second endogenous cannabinoid that modulates long-term potentiation.
  6. (2004). Aberrant cannabinoid signaling impairs oviductal transport of embryos.
  7. (1997). Accumulation of N-arachidonoylethanolamine (anandamide) into cerebellar granule cells occurs via facilitated diffusion.
  8. (1995). Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1.
  9. (2002). An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors.
  10. (1995). Analysis of anandamide, an endogenous cannabinoid substance, and of other natural Nacylethanolamines. Prostaglandins Leukot Essent Fatty Acids,
  11. (1994). Anandamide (arachidonylethanolamide), a brain cannabinoid receptor agonist, reduces sperm fertilizing capacity in sea urchins by inhibiting the acrosome reaction.
  12. (2004). Anandamide hydrolase: a guardian angel of human reproduction?
  13. (1998). Anandamide hydrolysis by human cells in culture and brain.
  14. (1995). Anandamide inhibits macrophage-mediated killing of tumor necrosis factor-sensitive cells.
  15. (2004). Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172.
  16. (2004). Anandamide Transport.
  17. (2000). Anandamide uptake by human endothelial cells and its regulation by nitric oxide.
  18. (2009). Anandamide-Induced Cell Death: Dual Effects in Primary Rat Decidual Cell Cultures.
  19. (1980). Anatomy and physiology of the fallopian tube.
  20. (1993). Antiphospholipid antibodies in pregnancy: prevalence and clinical associations.
  21. (2008). Appendix 1: Publications arising from this thesis 1. Ultra Performance Liquid Chromatography Tandem Mass Spectrometry Method for the Measurement of Anandamide in Human Plasma Analytical Biochemistry,
  22. (2008). Appendix 3: Ethics Documentation, patient information leaflet and consent forms.
  23. (2002). Balancing susceptibility to infection and autoimmunity: a role for leptin?
  24. (2007). Biochemistry in the diagnosis and management of abnormal early pregnancy.
  25. (1990). Can pregnancy-associated plasma protein A (PAPP-A) predict the outcome of pregnancy in women with threatened abortion and confirmed fetal viability?
  26. (2000). Cannabinoid agonist signal transduction in rat brain: comparison of cannabinoid agonists in receptor binding, G-protein activation, and adenylyl cyclase inhibition.
  27. (1992). Cannabinoid agonists stimulate both receptor- and non-receptormediated signal transduction pathways in cells transfected with and expressing cannabinoid receptor clones.
  28. (1995). Cannabinoid ligand-receptor signaling in the mouse uterus.
  29. (2005). Cannabinoid receptor I activation markedly inhibits human decidualization.
  30. (1990). Cannabinoid receptor localization in brain.
  31. (1993). Cannabinoid-receptor expression in human leukocytes.
  32. (2001). Cannabinoids activate p38 mitogen-activated protein kinases through CB1 receptors in hippocampus.
  33. (2004). Cannabinoids and the human uterus during pregnancy.
  34. (1967). Cannabis in early pregnancy.
  35. (2004). Cannabis, cannabinoids and reproduction. Prostaglandins Leukot Essent Fatty Acids,
  36. (2000). Carriermediated uptake of the endogenous cannabinoid anandamide in RBL-2H3 cells.
  37. (2003). Cellular accumulation of anandamide: consensus and controversy.
  38. (1997). Changes in anandamide levels in mouse uterus are associated with uterine receptivity for embryo implantation.
  39. (1997). Characterization of human chorionic gonadotropin in normal and abnormal pregnancies.
  40. (2001). Characterization of the 5'-sequence of the mouse fatty acid amide hydrolase.
  41. (2004). Characterization of the endocannabinoid system in early human pregnancy.
  42. (2004). Circulating endogenous cannabinoid anandamide and portal, systemic and renal hemodynamics in cirrhosis.
  43. (2004). Comparison of anandamide transport in FAAH wild-type and knockout neurons: evidence for contributions by both FAAH and the CB1 receptor to anandamide uptake.
  44. (1989). Conception to birth : epidemiology of prenatal development,
  45. (2007). Contemporary management of early pregnancy failure.
  46. (1990). Cytogenetic studies in couples experiencing repeated pregnancy losses.
  47. (1998). Cytokines and implantation.
  48. (2005). Day 14 maternal serum progesterone levels predict pregnancy outcome in IVF/ICSI treatment cycles: a prospective study.
  49. (2002). Deciphering the cross-talk of implantation: advances and challenges.
  50. (1998). Defective production of both leukemia inhibitory factor and type 2 T-helper cytokines by decidual T cells in unexplained recurrent abortions.
  51. (2002). Depression as a potential causal factor in subsequent miscarriage in recurrent spontaneous aborters.
  52. (1974). Depression of plasma testosterone levels after chronic intensive marihuana use.
  53. (2001). Design, synthesis and biological evaluation of novel arachidonic acid derivatives as highly potent and selective endocannabinoid transporter inhibitors.
  54. (1988). Determination and characterization of a cannabinoid receptor in rat brain.
  55. (2006). Determination of the endocannabinoid anandamide in human plasma by high-performance liquid chromatography.
  56. (2003). Differential effects on cognitive functioning in 13- to 16-year-olds prenatally exposed to cigarettes and marihuana.
  57. (2003). Differential G protein-coupled cannabinoid receptor signaling by anandamide directs blastocyst activation for implantation.
  58. (2006). Do serum leptin levels have a role in the prediction of pregnancy outcome in case of threatened miscarriage?
  59. (2000). Down-regulation of anandamide hydrolase in mouse uterus by sex hormones.
  60. (2001). Dysregulated cannabinoid signaling disrupts uterine receptivity for embryo implantation.
  61. (1969). Effect of marihuana extract on fetal hamsters and rabbits.
  62. (1995). Effects of anandamide (endogen cannabinoid) on anterior pituitary hormone secretion in adult ovariectomized rats.
  63. (2002). Effects of anandamide on embryo implantation in the mouse.
  64. (1997). Effects of anandamide on gestation in pregnant rats.
  65. (1989). Effects of maternal marijuana and cocaine use on fetal growth.
  66. (2000). Embryo implantation.
  67. (2000). Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide.
  68. (2002). Endocannabinoid signaling in synchronizing embryo development and uterine receptivity for implantation.
  69. (2002). Endocannabinoid signaling in synchronizing embryo development and uterine receptivity for implantation. Chem Phys Lipids,
  70. (2009). Endocannabinoid system in first trimester placenta: low FAAH and high CB1 expression characterize spontaneous miscarriage.
  71. (2002). Endocannabinoids, hormone-cytokine networks and human fertility. Prostaglandins Leukot Essent Fatty Acids,
  72. (1998). Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action.
  73. (1998). Endocannabinoids' and other fatty acid derivatives with cannabimimetic properties: biochemistry and possible physiopathological relevance.
  74. (2005). Endocrinology of pregnancy: consequences for the diagnosis and treatment of pregnancy disorders.
  75. (2001). Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses.
  76. (2002). Endogenous cannabinoids: metabolism and their role in reproduction.
  77. (2002). Epidemiologic measures of the course and outcome of pregnancy.
  78. (1996). Estimates of human fertility and pregnancy loss.
  79. (2003). Evidence against the presence of an anandamide transporter.
  80. (1993). Evidence for a cannabinoid receptor in sea urchin sperm and its role in blockade of the acrosome reaction.
  81. (2006). Evidence-based guidelines for the investigation and medical treatment of recurrent miscarriage.
  82. (2005). Expectant management of miscarriage--prediction of outcome using ultrasound and novel biochemical markers.
  83. (2002). Expression and regulation of the fatty acid amide hydrolase gene in the rat uterus during the estrous cycle and peri-implantation period.
  84. (1998). Expression of the CB1 and CB2 receptor messenger RNAs during embryonic development in the rat.
  85. (2008). Expression of the endocannabinoid system in human first trimester placenta and its role in trophoblast proliferation.
  86. (2003). Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system.
  87. (1999). Fatty-acid amide hydrolase is expressed in the mouse uterus and embryo during the periimplantation period.
  88. (2003). Fetal loss following ultrasound diagnosis of a live fetus at 6-10 weeks of gestation.
  89. (2004). First trimester levels of inhibins and activin A in normal and failing pregnancies.
  90. (2000). First trimester maternal serum free beta human chorionic gonadotrophin and pregnancy associated plasma protein A as predictors of pregnancy complications.
  91. (2004). Fluctuations of fatty acid amide hydrolase and anandamide levels during the human ovulatory cycle.
  92. (1994). Formation and inactivation of endogenous cannabinoid anandamide in central neurons.
  93. (2005). Further insights into the regulation of human FAAH by progesterone and leptin implications for endogenous levels of anandamide and apoptosis of immune and neuronal cells.
  94. (2001). Gas chromatography-mass spectrometry analysis of endogenous cannabinoids in healthy and tumoral human brain and human cells in culture.
  95. (2001). Highly selective CB(1) cannabinoid receptor ligands and novel CB(1)/VR(1) vanilloid receptor &quot;hybrid&quot; ligands.
  96. (1995). Highperformance liquid chromatography and fluorometric detection of arachidonylethanolamide (anandamide) and its analogues, derivatized with 4-(N-chloroformylmethyl-N-methyl)amino-7-N,N-dimethylaminosulp honyl-2,1 ,3- benzoxadiazole (DBD-COCl).
  97. (2005). History of Cannabis as a Medicine.
  98. (2004). Human chorionic gonadotrophin and progesterone levels in pregnancies of unknown location.
  99. (2000). Human chorionic gonadotropin as a predictor of outcome in assisted reproductive technology pregnancies.
  100. (2005). Human chorionic gonadotropin in cervical fluid as a predictor of miscarriage.
  101. (1995). Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors.
  102. (2001). Identification of modulators of GPR55 activity.
  103. (2003). Identification of the CB1 cannabinoid receptor and fatty acid amide hydrolase (FAAH) in the human placenta.
  104. (1998). Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system.
  105. (2001). Implantation and the survival of early pregnancy.
  106. (2006). Inactivation of N-acyl phosphatidylethanolamine phospholipase D reveals multiple mechanisms for the biosynthesis of endocannabinoids.
  107. (1988). Incidence of early loss of pregnancy.
  108. (1999). Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice.
  109. (1996). Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves.
  110. (1996). Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat.
  111. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor.[see comment].
  112. (1993). Isolation, identification and synthesis of an endogenous arachidonic amide that inhibits calcium channel antagonist 1,4-dihydropyridine binding. Prostaglandins Leukot Essent Fatty Acids,
  113. (2003). Leptin activates the anandamide hydrolase promoter in human T lymphocytes through STAT3.
  114. (2001). Leptin and leptin-binding activity in women with recurrent miscarriage: correlation with pregnancy outcome.
  115. (2001). Leptin-regulated endocannabinoids are involved in maintaining food intake.
  116. (2000). Ligand-receptor signaling with endocannabinoids in preimplantation embryo development and implantation. Chem Phys Lipids,
  117. (2005). Lipid signaling in embryo implantation.
  118. (1997). Liquid chromatographic-atmospheric pressure chemical ionization mass spectrometric determination of anandamide and its analogs in rat brain and peripheral tissues.
  119. (2009). Localisation and function of the endocannabinoid system in the human ovary.
  120. (2008). Loss of cannabinoid receptor CB1 induces preterm birth.
  121. (2002). Low fatty acid amide hydrolase and high anandamide levels are associated with failure to achieve an ongoing pregnancy after IVF and embryo transfer.
  122. (2004). Low levels of pregnancy-associated plasma protein-A in asymptomatic women destined for miscarriage.
  123. (1999). Low maternal serum PAPP-A and fetal viability.[comment].
  124. (1986). Marihuana smoking suppresses luteinizing hormone in women.
  125. (1986). Marihuana-induced embryotoxicity in the rabbit.
  126. (1995). Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide.
  127. (1983). Maternal alcohol, tobacco and cannabis consumption and the outcome of pregnancy.
  128. (2002). Maternal use of cannabis and pregnancy outcome.
  129. (1993). Molecular characterization of a peripheral receptor for cannabinoids.
  130. (1996). Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides.
  131. (1997). Morphine- and anandamide-stimulated nitric oxide production inhibits presynaptic dopamine release.
  132. (2002). N-Acylethanolamines in human reproductive fluids. Chem Phys Lipids,
  133. (2001). Normal human pituitary gland and pituitary adenomas express cannabinoid receptor type 1 and synthesize endogenous cannabinoids: first evidence for a direct role of cannabinoids on hormone modulation at the human pituitary level.
  134. (1997). Occurrence and biosynthesis of endogenous cannabinoid precursor, N-arachidonoyl phosphatidylethanolamine, in rat brain.
  135. (2005). Pharmacological actions of cannabinoids. Handb Exp Pharmacol,
  136. (1997). Pharmacology of cannabinoid CB1 and CB2 receptors.
  137. (2006). Plant, Synthetic, and Endogenous Cannabinoids in Medicine.
  138. (2008). Plasma anandamide concentration and pregnancy outcome in women with threatened miscarriage.
  139. (2004). Plasma levels of the endocannabinoid anandamide in women--a potential role in pregnancy maintenance and labor?
  140. (2002). Postsynaptic endocannabinoid release is critical to long-term depression in the striatum.
  141. (1999). Potential biochemical markers of uterine receptivity.
  142. (2006). Predicting the outcome of pregnancies of unknown location: Bayesian networks with expert prior information compared to logistic regression.
  143. (2003). Prediction of early pregnancy viability in the absence of an ultrasonically detectable embryo.
  144. (2003). Prediction of early pregnancy viability in the absence of an ultrasonically detectable embryo.[see comment].
  145. (1983). Pregnancy-associated plasma protein A in the prediction of early pregnancy failure.
  146. (2007). Pregnancy-associated plasma protein-A (PAPP-A): a local regulator of IGF bioavailability through cleavage of IGFBPs.
  147. (1983). Preimplantation development: biology, genetics, and mutagenesis.
  148. (2003). Prenatal exposure to a cannabinoid agonist produces memory deficits linked to dysfunction in hippocampal long-term potentiation and glutamate release.
  149. (1962). Probabilities of fetal mortality.
  150. (1997). Production and physiological actions of anandamide in the vasculature of the rat kidney.
  151. (2003). Progesterone activates fatty acid amide hydrolase (FAAH) promoter in human T lymphocytes through the transcription factor Ikaros. Evidence for a synergistic effect of leptin.
  152. (1995). Progesterone favors the development of human T helper cells producing Th2-type cytokines and promotes both IL-4 production and membrane CD30 expression in established Th1 cell clones.
  153. (2001). Progesterone up-regulates anandamide hydrolase in human lymphocytes: role of cytokines and implications for fertility.
  154. (2001). Progesterone up-regulates anandamide hydrolase in human lymphocytes. Role of cytokines and implications for fertility.
  155. (2000). Quantification of bioactive acylethanolamides in rat plasma by electrospray mass spectrometry.
  156. (2004). Quantification of whole blood anandamide by isotope dilution liquid chromotography - tandem mass spectrometry. Absract : Society for Neuroscience,
  157. (2007). Quantitative profiling of endocannabinoids and related compounds in rat brain using liquid chromatography-tandem electrospray ionization mass spectrometry.
  158. (1996). Regulation of a neuronal form of focal adhesion kinase by anandamide.
  159. (2003). Regulation of extracellular signal-regulated kinase by cannabinoids in hippocampus.
  160. (1996). Regulation of fetal allograft survival by a hormone-controlled Th1- and Th2-type cytokines.
  161. (1992). Regulation of ovarian steroid production.
  162. (2000). Relation between decreased anandamide hydrolase concentrations in human lymphocytes and miscarriage.
  163. (1999). Relationships between ligand affinities for the cerebellar cannabinoid receptor CB1 and the induction of GDP/GTP exchange.
  164. (2006). Release of anandamide from blood cells.
  165. (1978). Reproduction in rhesus monkeys chronically exposed to delta-9-tetrahydrocannabinol. Adv Biosci,
  166. (2008). Reproductive endocrinology and clinical aspects of obesity in women.
  167. (2002). Risk factors in miscarriage: a review.
  168. (2004). Screening assays for cannabinoid-ligand type modulators of GPR55. Patent WO2004074844.
  169. (2004). Serum concentrations of macrophage inhibitory cytokine 1 (MIC 1) as a predictor of miscarriage.
  170. (2002). Serum HCG 12 days after embryo transfer in predicting pregnancy outcome.
  171. (2000). Sex steroid influence on cannabinoid CB(1) receptor mRNA and endocannabinoid levels in the anterior pituitary gland.
  172. (1994). SR141716A, a potent and selective antagonist of the brain cannabinoid receptor.
  173. (1999). Stage-specific excitation of cannabinoid receptor exhibits differential effects on mouse embryonic development.
  174. (1999). Structural determinants for recognition and translocation by the anandamide transporter.
  175. (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA.
  176. (2000). Structure-activity relationships among Narachidonylethanolamine (Anandamide) head group analogues for the anandamide transporter.
  177. (1999). Substance misuse in early pregnancy and relationship to fetal outcome.
  178. (2001). Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase.
  179. (1998). The activation of cannabinoid receptors in striatonigral GABAergic neurons inhibited GABA uptake.
  180. (2000). The CB(1) cannabinoid receptor is coupled to the activation of c-Jun N-terminal kinase.
  181. (2000). The CB1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt.
  182. (1997). The effects of anandamide on memory consolidation in mice involve both D1 and D2 dopamine receptors.
  183. (1999). The effects of cannabinoids on the regulation of reproduction.
  184. (2000). The endocannabinoid system as a target for therapeutic drugs.
  185. (2004). The endocannabinoid system: a general view and latest additions.
  186. (2006). The endocannabinoid system: current pharmacological research and therapeutic possibilities.
  187. (2005). The endocrinological basis of recurrent miscarriages.
  188. (1996). The immunological pregnancy protective effect of progesterone is manifested via controlling cytokine production.
  189. (2007). The impact of obesity on female reproductive function.
  190. (1965). The isolation and structure of cannabinolic cannabidiolic and cannabigerolic acids.
  191. (1979). The non-specific binding properties of delta 9-tetrahydrocannabinol and the effects of various solubilizers.
  192. (2004). The one-stop recurrent miscarriage clinic: an evaluation of its effectiveness and outcome.
  193. (1994). The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice.
  194. (1995). The preimplantation mouse embryo is a target for cannabinoid ligand-receptor signaling.
  195. (1986). The prognostic value of HCG, PAPP-A, oestradiol-17 beta and progesterone in early human pregnancy.
  196. (2009). The relationship between plasma levels of the endocannabinoid, anandamide, sex steroids, and gonadotrophins during the menstrual cycle. Fertil Steril.
  197. (1996). The significance of extrachorionic membrane separation in threatened miscarriage.
  198. (1996). The uterus is a potential site for anandamide synthesis and hydrolysis: differential profiles of anandamide synthase and hydrolase activities in the mouse uterus during the periimplantation period.
  199. (1998). The value of biochemical and ultrasound measurements in predicting pregnancy outcome in women with a history of recurrent miscarriage.
  200. (1999). Threatened abortion: prediction of viability based on signs and symptoms.
  201. (2006). Threatened miscarriage as a predictor of obstetric outcome.
  202. (2004). Threatened miscarriage: evaluation and management.
  203. (2002). Transcriptional regulation of the mouse fatty acid amide hydrolase gene.
  204. (2006). Type-1 cannabinoid receptor expression in the frog, Rana esculenta, tissues: a possible involvement in the regulation of testicular activity.
  205. (2003). Ultrasound prediction of risk of spontaneous miscarriage in live embryos from assisted conceptions.
  206. (1999). Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice.
  207. (2006). Uterine natural killer cells, implantation failure and recurrent miscarriage.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.